Drug Trial Radar · NCT00369837
Clevidipine in the Treatment of Patients With Severe Hypertension (VELOCITY)
Last checked: Nov 20, 2026Latest source record: May 22, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
131
Actual
Start
Sep 2006
Primary completion
Jan 2007
Study completion Feb 2007
Sponsor
- Lead sponsor
- The Medicines CompanyIndustry
- Sponsor type
- Industry
- First posted
- Aug 29, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to determine the safety of clevidipine for treating severely elevated blood pressure, defined as systolic (SBP) \>180 mmHg and/or diastolic blood pressure (DBP) \>115 mmHg assessed on 2 successive occasions 15 minutes apart at baseline, in patients with or without major organ injury, particularly with respect to controlled dose adjustment to desired effect and prolonged continuous infusion. Enrollment of patients into the study was to continue until the target goal of 100 patients with at least 18 hours of continuous clevidipine treatment, including a minimum of 50 patients with acute or chronic end-organ injury, was met.
Conditions
- Hypertension
Interventions
clevidipineDrug
Clevidipine was required to be administered continuously for a minimum of 18 hours and a maximum of 96 hours and was not to exceed a rate of 32.0 mg/h at any time. Use of an additional or alternative intravenous antihypertensive agent was allowed if the blood pressure target range was not achieved or maintained. If transition to an oral antihypertensive agent is required, then approximately 1 hour prior to the anticipated cessation of clevidipine infusion, but no less than at the 18-hour time point, an oral antihypertensive agent was allowed to be administered as clevidipine was down-titrated or terminated as needed in order to achieve the desired blood pressure level..
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of patients in whom SBP falls below the lower limit of the patient-specific, pre-determined blood pressure target range at the initial dose (2.0 mg/h)Time frame: Study drug initiation through the first 3 minutes of the infusion
- Percentage of patients who reach the prespecified target SBP rangeTime frame: Within 30 minutes of the initiation of the infusion
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
Jackson Hospital
Montgomery, Alabama
VA Medical Center W. LA
Los Angeles, California
The George Washington University Medical Center
Washington D.C., District of Columbia
Louisiana State University Medical Center/Charity Hospital
New Orleans, Louisiana
Critical Care Research Center at Louisiana State University Health Sciences Center
Shreveport, Louisiana
Good Samaritan Hospital
Baltimore, Maryland
Duke University Medical Center
Durham, North Carolina
Metrohealth Medical Center
Cleveland, Ohio
The Cleveland Clinic
Cleveland, Ohio
The Toledo Hospital
Toledo, Ohio
Providence Heart & Vascular Institute, d/b/a Providence St. Vincent Medical Center
Portland, Oregon
Hamot Shock Trauma
Erie, Pennsylvania
Pennsylvania Hospital
Philadelphia, Pennsylvania
The University of Texas Health Science Center
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.